Latest Updates
eXoZymes Inc.
eXoZymes Inc. (Nasdaq: EXOZ) is a biotechnology company that has developed a new way to produce chemicals without using living cells. The company's technology, called "exozymes," combines enzymes (proteins that speed up chemical reactions) with artificial intelligence to create a manufacturing platform that transforms biomass into chemicals, medicines, and fuels. Unlike traditional synthetic biology that relies on living cells, eXoZymes' cell-free approach operates more like industrial chemistry, avoiding the common problems that prevent biological manufacturing from reaching commercial scale.
Stock Information
Investor Presentation
Stock Details
Recent News
SEC Filings
eXoZymes Inc. At A Glance
eXoZymes Inc. is a biotechnology company that has developed a cell-free biomanufacturing platform to produce chemicals, medicines, and fuels without using living cells. The company's technology combines artificial intelligence with enhanced enzymes (called "exozymes") that function in bioreactors to transform biomass into target chemicals. By removing cells from the manufacturing process, eXoZymes addresses the scaling bottleneck that has historically limited commercial success in synthetic biology. With approximately $14 million in U.S. government grants and a platform-of-platforms business model focused on licensing and partnerships, eXoZymes aims to enable sustainable, scalable alternatives to traditional petrochemical production methods.
eXoZymes' Platform Solves Industry Bottleneck
The company's technology addresses why most synthetic biology projects fail commercially. Traditional cell-based manufacturing faces three major problems: cells die from toxic chemicals, cells naturally resist producing unneeded chemicals, and extracting pure chemicals from cell mixtures costs more than the chemicals are worth. eXoZymes eliminates these issues by removing cells entirely from the equation, using engineered enzymes that work in bioreactors without cellular limitations.
$14 Million in Government Validation
eXoZymes has received approximately $14 million in U.S. government grants from agencies including the National Institutes of Health, Department of Energy, and Department of Defense. These grants have funded development across multiple applications including sustainable aviation fuel (isobutanol), cannabinoids, proteins, and other chemicals. Government funding provides both validation of the technology and non-dilutive capital for development.
Platform-of-Platforms Business Model
Rather than competing directly in chemical markets, eXoZymes licenses its technology to partners who handle production and commercialization. The company generates revenue through licensing fees, royalties (typically 1-8%), and sales of proprietary enzymes. This capital-light approach allows eXoZymes to address multiple markets simultaneously without the infrastructure costs of manufacturing facilities.
NCT: First Commercial Application
The company has developed a biosolution for N-trans-Caffeoyltyramine (NCT), a compound with pharmaceutical potential for treating fatty liver disease and inflammatory bowel disease. NCT has been validated in peer-reviewed studies as a potent HNF4a agonist and was shown to be non-toxic at the highest doses tested. This represents eXoZymes' first demonstration of producing a high-value pharmaceutical compound using its platform.
Sustainable Aviation Fuel Opportunity
eXoZymes is developing technology to produce isobutanol for use as sustainable aviation fuel (SAF), which reduces CO2 emissions by up to 80% compared to fossil fuels. The aviation fuel market is projected to grow from $220 billion in 2022 to $793 billion by 2030, with government mandates requiring 70% of EU airport fuel to be SAF by 2050. The company has received $5.7 million in Department of Energy and Department of Defense grants for this application.
Proprietary AI and Enzyme Engineering
The company combines proprietary enzyme engineering capabilities with artificial intelligence to design and optimize enzyme pathways. This includes over 10 patents and substantial trade secrets covering novel enzymes, cell-free manufacturing processes, and specific chemical products. The technology has been validated through publications in peer-reviewed journals including Nature Chemical Biology and Nature Communications.
Important Resources
Including an At-A-Glance PDF, a document tailored to those who just want quick and summarized information.
eXoZymes Inc. management brings together biotechnology and commercial expertise.
The team combines scientific leadership from UCLA with business executives experienced in scaling technology companies, leveraging deep knowledge in enzyme engineering, artificial intelligence, and biomanufacturing to develop and commercialize cell-free production solutions for partners worldwide
The eXoZymes Inc. executive leadership regularly updates investors with company news. Please fill out this form to receive the latest information.
Note: The company can only disclose information that is shared in the public domain through press releases, SEC filings, and other public forums. As securities law and industry regulations require, such information will always be shared with all investors simultaneously.
